Summary of Study ST003313
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002060. The data can be accessed directly via it's Project DOI: 10.21228/M8BG0T This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST003313 |
| Study Title | Integrative analysis of serum and fecal metabolome and the microbiome that herald Crohn Disease flare - feces |
| Study Summary | We investigated the relationship between the host and gut microbiota in the context of Crohn Disease (CD), which is a relapsing-remitting condition. We analyzed paired omics of 80 CD patients and 43 controls, including 202 serum and 294 fecal metabolomics, and 258 microbiome samples. Our findings suggest that CD patients have an inverse shift in energy utilization from sugars and fat between serum and feces. In the serum, we noted a decrease in metabolites related to starch, sucrose, and tricarboxylic acid (TCA) cycle, as well as an increase in metabolites linked to fat in contrast to the feces, where we noted higher sugars and TCA cycle metabolites, and lower fat metabolites. Interestingly, fecal sugars were specifically linked with oral bacteria mislocated to the CD gut, while unsaturated fat derivatives of arachidonic acid were linked with R. gnavus and Fusobacteria. We identified consistent metabolite alterations in CD patients, which were also present in clinical/biomarkers active CD, and pre-flare samples of patients who experienced flare. Using pre-flare samples, we developed models that predicted a subsequent flare using metabolic serum and fecal signatures. We validated the fecal metabolomics predictions in another, similarly designed, independent CD cohort. Finally, we developed a clinical lab-based index [UA/Cr ratio+log2(CRP)] based on the serum metabolomics model, which was also predictive in the validation cohort. Here are the fecal metabolomics samples. |
| Institute | Sheba hospital |
| Last Name | Braun |
| First Name | Tzipi |
| Address | Sheba hospital, Ramat Gan, Ramat Gan, 52621, Israel |
| zipik0@gmail.com | |
| Phone | 97235305000 |
| Submit Date | 2024-06-19 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML |
| Analysis Type Detail | Other |
| Release Date | 2024-08-01 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
| Analysis ID | AN005425 |
|---|---|
| Analysis type | MS |
| Chromatography type | HILIC |
| Chromatography system | Thermo Dionex |
| Column | SeQuant ZIC-pHILIC (150 x 2.1mm,5um) |
| MS Type | ESI |
| MS instrument type | Orbitrap |
| MS instrument name | Thermo Q Exactive Orbitrap |
| Ion Mode | UNSPECIFIED |
| Units | percentage of metabolites per sample |
MS:
| MS ID: | MS005151 |
| Analysis ID: | AN005425 |
| Instrument Name: | Thermo Q Exactive Orbitrap |
| Instrument Type: | Orbitrap |
| MS Type: | ESI |
| MS Comments: | Orbitrap Q-Exactive Mass Spectrometer (Thermo Fisher Scientific) was used. The resolution was set to 35,000 at a 200 mass/charge ratio (m/z) with electrospray ionization and polarity switching mode to enable both positive and negative ions across a mass range of 67–1000 m/z. The raw data files generated by UPLC-MS/MS were processed using the MassLynx software (v4.1, Waters, Milford, MA, USA) to perform peak integration, calibration, and quantitation for each metabolite. |
| Ion Mode: | UNSPECIFIED |
